Kezar Life Sciences (NASDAQ:KZR) Announces Earnings Results

Kezar Life Sciences (NASDAQ:KZR) announced its quarterly earnings results on Tuesday. The company reported ($2.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.71) by ($0.06), Zacks reports.

Kezar Life Sciences Price Performance

Shares of NASDAQ KZR opened at $5.17 on Thursday. The company’s fifty day moving average is $6.05 and its two-hundred day moving average is $6.70. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.65 and a current ratio of 7.65. The firm has a market capitalization of $37.72 million, a P/E ratio of -0.39 and a beta of 0.49. Kezar Life Sciences has a one year low of $5.01 and a one year high of $9.38.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on KZR shares. Wells Fargo & Company decreased their target price on Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 19th. William Blair reiterated an “outperform” rating on shares of Kezar Life Sciences in a research report on Friday, February 28th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, December 2nd.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.